3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms, Male
1
Interventions
Bevacizumab
56
Cetuximab
50
Fluorouracil
45
Leucovorin
39
Oxaliplatin
38
pembrolizumab
31
Specimen Handling
27
Irinotecan
25
Magnetic Resonance Spectroscopy
17
Biopsy
17
Nivolumab
15
HMPL-013
13
Folfox protocol
13
Capecitabine
13
Gemcitabine
12
Cisplatin
12
trifluridine tipiracil drug combination
11
Panitumumab
11
Carboplatin
11
Pemetrexed
9
IFL protocol
9
encorafenib
8
balstilimab
8
Standard of Care
8
Paclitaxel
8
Early Intervention, Educational
8
130-nm albumin-bound paclitaxel
8
fludarabine
7
atezolizumab
7
Educational Status
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
Genetic Counseling
×
90 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled